





Figura 2: Porcentaje de adsorción de la hepatitis B, datos con la formulación inicial junto con la línea de cinética y el límite inferior unilateral del 99 %



Los datos farmacéuticos y clínicos disponibles demuestran que el producto es seguro e inmunogénico y cumple con los estándares de calidad requeridos durante la vida útil de 36 meses. Utilizando el modelo de curva cinética de mejor ajuste y el límite de confianza unilateral inferior del 99 %, se justifica un criterio de aceptación para la vida útil del porcentaje de hepatitis B a los 36 meses mayor o igual que 28 % para los estudios de estabilidad futuros.

^a FP(S): lotes de producto llenado en jeringas monodosis con la formulación inicial
FP(V): lotes de producto llenado en viales monodosis con la formulación inicial





5 Conclusión general

Los datos de estabilidad de respaldo se resumen en la Tabla 14.

Tabla 14: Resumen de los datos de estabilidad de respaldo

Estudio	Producto almacenado	Formulación	Envase y sellos de cierre	Condiciones de almacenamiento
Estudio 1	PFAG de MLE	Formulación optimizada	Tanques de acero inoxidable	+5°C ± 3°C
Estudio 2	PF de MLE	Formulación inicial	Jeringas monodosis	+5°C ± 3°C
Estudio 3	PF de MLE	Formulación optimizada	Jeringas monodosis	+5°C ± 3°C +25°C ± 2°C
Estudio 4	PF de Anagni	Formulación inicial	Viales monodosis	+5°C ± 3°C
Estudio 5	PF de VDR	Formulación optimizada	Viales monodosis	+5°C ± 3°C +25°C ± 2°C

Basándose en los resultados obtenidos en condiciones a largo plazo, se declara una vida útil de 9 meses para el producto final a granel.

Basándonos en los resultados obtenidos en condiciones a largo plazo y en el estudio de comparabilidad (vea la sección 3.2.P.2.3 Desarrollo del proceso de elaboración), se declara una vida útil de 36 meses para el producto llenado almacenado en viales y jeringas monodosis.

Además, estos estudios permiten definir pruebas indicadoras de estabilidad monitoreadas para los estudios de estabilidad futuros durante el programa de estabilidad anual, como se describe en la sección 3.2.P.5.1 Especificaciones.






Section 3.2.P.8.3 - Stability Data

Table of Contents

List of Tables.....	2
1 Stability Results.....	3
1.1 Study 1: Marcy l'Etoile Final Bulk Product – Optimized Formulation – Stability Data on Long-Term Storage Conditions at +5°C ± 3°C.....	3
1.2 Study 2: Marcy l'Etoile Filled Product – Initial Formulation – Stability Data on Long-Term Storage Conditions at +5°C ± 3°C.....	3
1.3 Study 3: Marcy l'Etoile Filled Product – Optimized Formulation – Stability Data on Long-Term Storage Conditions at +5°C ± 3°C.....	3
1.4 Study 3: Marcy l'Etoile Filled Product – Optimized Formulation – Stability Data on Accelerated Storage Conditions at +25°C ± 2°C.....	3
1.5 Study 4: Anagni Filled Product – Initial Formulation – Stability Data on Long-Term Storage Conditions at +5°C ± 3°C.....	3
1.6 Study 5: Val de Reuil Filled Product – Optimized Formulation – Stability Data on Long-Term Storage Conditions at +5°C ± 3°C.....	3
1.7 Study 5: Val de Reuil Filled Product – Optimized Formulation – Stability Data on Accelerated Storage Conditions at +25°C ± 2°C.....	3
2 Analytical Procedures.....	3
2.1 Summary of Analytical Procedures.....	3
2.1.1 <i>Haemophilus</i> Immunogenicity.....	3
2.1.2 Non-Adsorbed PT and Non-Adsorbed FHA.....	3
2.1.3 Percent Adsorption - Tetanus Toxoid (Rocket).....	3
2.1.4 Rat Immunogenicity Assay for IPV.....	3
2.1.5 Specific Toxicity for Diphtheria and Tetanus Components.....	3
2.1.6 Integrity Test.....	3
2.2 Summary of Validation of Analytical Procedures.....	3
2.2.1 Non-Adsorbed PT and Non-Adsorbed FHA.....	3
2.2.2 Percent Adsorption – Tetanus Toxoid (Rocket).....	3
2.2.3 Rat Immunogenicity Assay for IPV.....	3
2.2.4 Integrity Test.....	3





List of Tables

Table 1: Stability Study Results for Marcy l'Etoile Final Bulk Product Batch FDV01398 at +5°C ± 3°C3

Table 2: Stability Study Results for Marcy l'Etoile Final Bulk Product Batch FDV01416 at +5°C ± 3°C3

Table 3: Stability Study Results for Marcy l'Etoile Final Bulk Product Batch FDV01420 at +5°C ± 3°C3

Table 4: Stability Study Results for Marcy l'Etoile Filled Product Batch S4009 at +5°C ± 3°C3

Table 5: Stability Study Results for Marcy l'Etoile Filled Product Batch S4106 at +5°C ± 3°C3

Table 6: Stability Study Results for Marcy l'Etoile Filled Product Batch S4107 at +5°C ± 3°C3

Table 7: Stability Study Results for Marcy l'Etoile Filled Product Batch FDNC0491 at +5°C ± 3°C3

Table 8: Stability Study Results for Marcy l'Etoile Filled Product Batch FDNC0504 at +5°C ± 3°C3

Table 9: Stability Study Results for Marcy l'Etoile Filled Product Batch FDNC0505 at +5°C ± 3°C3

Table 10: Stability Study Results for Marcy l'Etoile Filled Product Batch FDNC0491 at +25°C ± 2°C3

Table 11: Stability Study Results for Marcy l'Etoile Filled Product Batch FDNC0504 at +25°C ± 2°C3

Table 12: Stability Study Results for Marcy l'Etoile Filled Product Batch FDNC0505 at +25°C ± 2°C3

Table 13: Stability Study Results for Anagni Filled Product Batch S4114 at +5°C ± 3°C.....3

Table 14: Stability Study Results for Anagni Filled Product Batch S4115 at +5°C ± 3°C.....3

Table 15: Stability Study Results for Anagni Filled Product Batch S4116 at +5°C ± 3°C.....3

Table 16: Stability Study Results for Val de Reuil Filled Product Batch S4312 at +5°C ± 3°C3

Table 17: Stability Study Results for Val de Reuil Filled Product Batch S4313 at +5°C ± 3°C3

Table 18: Stability Study Results for Val de Reuil Filled Product Batch S4314 at +5°C ± 3°C3

Table 19: Stability Study Results for Val de Reuil Filled Product Batch S4312 at +25°C ± 2°C3

Table 20: Stability Study Results for Val de Reuil Filled Product Batch S4313 at +25°C ± 2°C3

Table 21: Stability Study Results for Val de Reuil Filled Product Batch S4314 at +25°C ± 2°C3

Table 22: Test Methods Used for Stability Studies.....3

Table 23: Titration of Pertussis Toxoid by ELISA in the Hexaxim Supernatant - Validation Summary.....3






Table 24: Absorbance of the Hexaxim Matrix Supernatants without PTxd Antigen versus Absorbance of the Hexaxim Matrix Supernatant3

Table 25: Absorbance of the Hexaxim Matrix Supernatant without PTxd Antigen Spiked with 0.023 µg/mL of PTxd versus Absorbance at the Detection Threshold and Absorbance of the PTxd Positive Control3

Table 26: Titration of FHA by ELISA in the Hexaxim Supernatant - Validation Summary3

Table 27: Absorbance of the Hexaxim Matrix Supernatants without FHA Antigen versus Absorbance of the Hexaxim Matrix Supernatant3

Table 28: Absorbance of the Hexaxim Matrix Supernatant without FHA Antigen Spiked with 0.043 µg/mL of FHA versus Absorbance at the Detection Threshold and Absorbance of the FHA Positive Control3

Table 29: Percent Adsorption – Tetanus Toxoid (Rocket) – Validation - Summary3

Table 30: Specificity: Results3

Table 31: Linearity: Measured Concentrations versus Theoretical Concentrations (Lf/mL)3

Table 32: Linearity - Equation of the Straight Regression Line3

Table 33: Accuracy: Mean Percent Recoveries by Concentration3

Table 34: Precision: Concentration of Non-Adsorbed Purified Tetanus Toxoid (Lf/mL) and % of Adsorption3

Table 35: Precision: Repeatability and Intermediate Precision Characteristics3

Table 36: Precision: Repeatability and Intermediate Precision Characteristics3

Table 37: Rat Immunogenicity Assay for IPV - Validation Summary3

Table 38: Intermediate Precision - Rounded Endpoint Titers for In-House Standard Serum - Verification Test Number 13

Table 39: Intermediate Precision - Rounded Endpoint Titers for In-House Standard Serum - Verification Test Number 23

Table 40: Intermediate Precision - Comparison of Antibody - Verification Test Number 13

Table 41: Intermediate Precision - Comparison of Antibody - Verification Test Number 23

Table 42: Limit of Detection - Fluorescence Results according the Quantities of Adding Solutions3

Table 43: Specificity - Results of Integrity Test3

Table 44: Sealing System Qualification - Results of Fluorescent Vials/Syringes3





List of abbreviations: see 2.3 Quality Overall Summary, Introduction

1 Stability Results

This chapter provides the stability data results for the studies presented in 3.2.P.8.1 Stability Summary and Conclusions. The tests not planned in the stability protocol are abbreviated as follow: NP.

1.1 Study 1: Marcy l'Etoile Final Bulk Product – Optimized Formulation – Stability Data on Long-Term Storage Conditions at $+5^{\circ}\text{C} \pm 3^{\circ}\text{C}$

9 months stability data with the optimized formulation on 3 batches of MLE FBP are presented in Table 1 to Table 3.



sanofi pasteur
352 - Hexaxim

Table 1: Stability Study Results for Marcy l'Etoile Final Bulk Product Batch FDV01398 at +5°C ± 3°C

Tests	Acceptance criteria	T0	1 month	2 months	3 months	4 months	5 months	6 months	9 months
Appearance	Whitish and cloudy suspension	Conforms	NP*	NP	Conforms	NP	NP	Conforms	Conforms
pH measurement	6.5 - 7.5	7.21	NP	NP	7.28	NP	NP	7.31	7.31
Free formaldehyde content	≤ 30 µg/mL	3.23	NP	NP	0.50	NP	NP	<0.36	<0.36
Aluminium content	0.80 - 1.60 mg/mL	1.15	NP	NP	1.22	NP	NP	1.20	1.22
Osmolality measurement	300 - 400 mosmol/kg	338	NP	NP	338	NP	NP	337	335
Non-adsorbed PRP	≥ 16 µg/mL	22.6	23.1	23.3	24.9	24.2	22.2	27.7	27.0
Depolymerized PRP	For information (%)	9.1	7.1	10.7	12.3	12.0	12.9	17.4	22.9
Diphtheria potency: Activity	Activity ≥ 60 IU/mL	84	NP	NP	154	NP	NP	138	92
Lower limit	Lower confidence limit ($P = 0.95$) of the estimated potency	68			110			100	66
Upper limit	≥ 40 IU/mL	104			222			194	126
Tetanus potency: Activity	Lower confidence limit ($P = 0.95$) of the estimated potency	1112	NP	NP	1970	NP	NP	1152	1426
Lower limit	≥ 80 IU/mL	560			1448			800	1042
Upper limit		1706			2740			1830	1942
Histamine-sensitizing activity	≥ 95% survival (%)	100	NP	NP	100	NP	NP	100	100
Pertussis immunogenicity anti-FHA	Anti-Filamentous Hemagglutinin (FHA) antibody titer obtained for the vaccine is not significantly ($P = 0.95$) less than that of the reference vaccine	Conforms	NP	NP	Conforms	NP	NP	Conforms	Conforms

ROXANA MUNTEMILOM
DIRECTORA TÉCNICA
SANOFI PASTEUR S.A.

CHRISTIAN DOMINGUEZ
APODERADO
SANOFI PASTEUR S.A.

RA_0301822




sanofi pasteur
352 - Hexaxim

Tests	Acceptance criteria	T0	1 month	2 months	3 months	4 months	5 months	6 months	9 months
Pertussis immunogenicity anti-PT	Anti-Pertussis Toxoid (PTxd) and antibody titer obtained for the vaccine is not significantly ($P = 0.95$) less than that of the reference vaccine	Conforms	NP	NP	Conforms	NP	NP	Conforms	Conforms
Haemophilus immunogenicity	Not less than 50% of the vaccinated mice are seroconverted. Their titer is not less than 4 times that of the pooled control serum	Conforms	NP	NP	Conforms	NP	NP	Conforms at 8 months	Conforms
Non-adsorbed PT	For information ($\mu\text{g/mL}$)†	<2.5	NP	NP	<2.5	NP	NP	<2.5 at 8 months	<2.5
Non-adsorbed FHA	For information ($\mu\text{g/mL}$)†	<2.5	NP	NP	<2.5	NP	NP	<2.5 at 7 months	<2.5
Percent adsorption – tetanus toxoid	For information (%)	23	NP	NP	33	NP	NP	35	28
Percent adsorption – diphtheria toxoid	For information (%)	46	NP	NP	54	NP	NP	53	54
Rat immunogenicity assay for IPV	For information (relative potency)								
Type 1		0.7	NP	NP	NP	NP	NP	1.3	1.0
Type 2		0.6	NP	NP	NP	NP	NP	0.8	2.1
Type 3		1.9	NP	NP	NP	NP	NP	0.6	1.1
D-antigen content	Type 1: 40 – 86 DU†/mL	53.8	NP	NP	60.1	NP	NP	53.6	52.5
	Type 2: 10 – 18 DU/mL	11.0	NP	NP	12.1	NP	NP	11.4	10.8
	Type 3: 34 – 72 DU/mL	52.6	NP	NP	52.0	NP	NP	47.9	49.7 at 10 months
Percent adsorption – hepatitis B (ELISA)	For information (%)	95	92	92	91	89	85	89	88



OXANA MONTEMILOM DIRECTORA TÉCNICA SANOFI PASTEUR S.A.
CHRISTIAN DOMINGUEZ APODERADO SANOFI PASTEUR S.A.



Section 3.2.P.8.3
Stability Data

sanofi pasteur
352 - Hexaxim

Tests	Acceptance criteria	T0	1 month	2 months	3 months	4 months	5 months	6 months	9 months
Hepatitis B <i>in-vitro</i> relative potency (IVRP)	For information (relative potency)	1.22	NP	NP	1.34	NP	NP	1.51	1.45
Hepatitis B immunogenicity	Upper confidence limit (P = 0.95) of the estimated relative potency is not less than 1.0	1.21	NP	NP	1.23	NP	NP	1.00	1.05
Lower limit		0.628	NP	NP	0.703	NP	NP	0.576	0.619
Upper limit		2.561	NP	NP	2.293 at 4 months	NP	NP	1.736	1.813
Bacterial and fungal sterility test	No microbial growth	Conforms	NP	NP	NP	NP	NP	Conforms	Conforms

* Not Planned as per protocol

† Expected value: $\leq 2.5 \mu\text{g/mL}$

‡ DU: D-antigen Unit

ROXANA M. INTEMILONE
DIRECTORA TÉCNICA
SANOFI PASTEUR S.A.

CHRISTIAN DOMINGUEZ
APODERADO
SANOFI PASTEUR S.A.




sanofi pasteur
352 - Hexaxim

Table 2: Stability Study Results for Marcy l'Etoile Final Bulk Product Batch FDV01416 at +5°C ± 3°C

Tests	Acceptance criteria	T0	1 month	2 months	3 months	4 months	5 months	6 months	9 months
Appearance	Whitish and cloudy suspension	Conforms	NP*	NP	Conforms	NP	NP	Conforms	Conforms
pH measurement	6.5 - 7.5	7.11	NP	NP	7.18	NP	NP	7.22	7.20
Free formaldehyde content	≤ 30 µg/mL	3.34	NP	NP	0.47	NP	NP	0.41	< 0.36
Aluminium content	0.80 - 1.60 mg/mL	1.21	NP	NP	1.21	NP	NP	1.20	1.23
Osmolality measurement	300 - 400 mosmol/kg	338	NP	NP	335	NP	NP	336	335
Non-adsorbed PRP	≥ 16 µg/mL	20.0	19.5	21.6	22.6	22.0	22.7	22.9	24.8
Depolymerized PRP	For information (%)	3.7	5.7	6.3	16.1	10.6	11.5	18.4	18.4
Diphtheria potency :	Activity ≥ 60 IU/mL								
Activity	Lower confidence limit (P = 0.95)	114	NP	NP	102	NP	NP	116	148
Lower limit	of the estimated potency	86			72			76	102
Upper limit	≥ 40 IU/mL	164			144			182	218
Tetanus Potency :	Lower confidence limit (P = 0.95)								
Activity	of the estimated potency	1168	NP	NP	1724	NP	NP	1568	1652
Lower limit	≥ 80 IU/mL	826			1162			1168	1042
Upper limit		1590			3106			2110	2332
Histamine-sensitizing activity	≥ 95% survival (%)	100	NP	NP	100	NP	NP	100	100

ROXANA MONTEMILONE DIRECTORA TECNICA SANOFI PASTEUR S.A.
CHRISTIAN DOMINGUEZ APODERADO SANOFI PASTEUR S.A.





sanofi pasteur
352 - Hexaxim

Tests	Acceptance criteria	T0	1 month	2 months	3 months	4 months	5 months	6 months	9 months
Pertussis immunogenicity anti-FHA	Anti-Filamentous Hemagglutinin (FHA) antibody titer obtained for the vaccine is not significantly ($P = 0.95$) less than that of the reference vaccine	Conforms	NP	NP	Conforms	NP	NP	Conforms	Conforms
Pertussis immunogenicity anti-PT	Anti-Pertussis Toxoid (PTx) and antibody titer obtained for the vaccine is not significantly ($P = 0.95$) less than that of the reference vaccine	Conforms	NP	NP	Conforms	NP	NP	Conforms	Conforms
Haemophilus immunogenicity	Not less than 50% of the vaccinated mice are seroconverted. Their titer is not less than 4 times that of the pooled control serum	Conforms	NP	NP	Conforms at 4 months	NP	NP	Conforms at 7.5 months	Conforms
Non-adsorbed PT	For information ($\mu\text{g/mL}$)†	<2.5	NP	NP	<2.5	NP	NP	<2.5	<2.5
Non-adsorbed FHA	For information ($\mu\text{g/mL}$)†	<2.5	NP	NP	<2.5	NP	NP	<2.5	<2.5
Percent adsorption – tetanus toxoid	For information (%)	33	NP	NP	27	NP	NP	39	41
Percent adsorption – diphtheria toxoid	For information (%)	54	NP	NP	55	NP	NP	55	63
Rat immunogenicity assay for IPV	For information (relative potency)								
Type 1		0.5	NP	NP	NP	NP	NP	Invalid test†	0.9
Type 2		0.5	NP	NP	NP	NP	NP	Invalid test†	1.3
Type 3		1.6	NP	NP	NP	NP	NP	0.4	0.7
D-antigen content	Type 1: 40 – 86 DU/mL Type 2: 10 – 18 DU/mL Type 3: 34 – 72 DU/mL	57.5 12.0 51.3	NP NP NP	NP NP NP	57.4 12.0 51.3	NP NP NP	NP NP NP	53.9 11.8 50.4	54.7 11.2 53.3

ROXANA M. INTERMILONE DIRECTORA TÉCNICA SANOFI PASTEUR S.A.
CHRISTIAN DOMINGUEZ APODERADO SANOFI PASTEUR S.A.

RA_0301822

Confidential/Proprietary Information
Page 9 of 111





sanofi pasteur
352 - Hexaxim

Tests	Acceptance criteria	T0	1 month	2 months	3 months	4 months	5 months	6 months	9 months
Percent adsorption – hepatitis B (ELISA)	For information (%)	97	93	92	90	90	88	88	86
Hepatitis B <i>in-vitro</i> relative potency (IVRP)	For information (relative potency)	1.18	NP	NP	1.15	NP	NP	1.32	1.53
Hepatitis B Immunogenicity	Upper confidence limit (P = 0.95) of the estimated relative potency is not less than 1.0	1.16	NP	NP	1.05	NP	NP	1.09	1.47
Lower limit		0.638	NP	NP	0.570	NP	NP	0.631	0.901
Upper limit		2.041	NP	NP	2.087	NP	NP	1.983	2.793
Bacterial and fungal sterility test	No microbial growth	Conforms	NP	NP	NP at 3.5 months	NP	NP	Conforms	Conforms

* Not Planned as per protocol

† Expected value: ≤ 2.5 µg/mL

‡ No retest because of proximity of next time point

ROXANA MONTEMILONE
DIRECTORA TÉCNICA
SANOFI PASTEUR S.A.

CHRISTIAN DOMINGUEZ
APODERADO
SANOFI PASTEUR S.A.

RA_0301822





sanofi pasteur
352 - Hexaxim

Table 3: Stability Study Results for Marcy l'Etoile Final Bulk Product Batch FDV01420 at +5°C ± 3°C

Tests	Acceptance criteria	T0	1 month	2 months	3 months	4 months	5 months	6 months	9 months
Appearance	Whitish and cloudy suspension	Conforms	NP*	NP	Conforms	NP	NP	Conforms	Conforms
pH measurement	6.5 - 7.5	7.13	NP	NP	7.21	NP	NP	7.26	7.24
Free formaldehyde content	≤ 30 µg/mL	1.36	NP	NP	<0.36	NP	NP	<0.36	<0.36
Aluminium content	0.80 - 1.60 mg/mL	1.17	NP	NP	1.21	NP	NP	1.19	1.21
Osmolality measurement	300 - 400 mosmol/kg	336	NP	NP	334	NP	NP	332	333
Non-adsorbed PRP	≥ 16 µg/mL	21.0	20.4	22.9	23.1	20.7	24.5	21.6	23.9
Depolymerized PRP	For information (%)	7.3	11.0	9.5	9.3	12.0	16.2	18.0	22.9
Diphtheria potency : Activity	Activity ≥ 60 IU/mL	152	NP	NP	176	NP	NP	140	190
Lower limit	Lower confidence limit (P = 0.95) of the estimated potency ≥ 40 IU/mL	114			132			102	116
Upper limit		226			240			196	296
Tetanus Potency : Activity	Lower confidence limit (P = 0.95) of the estimated potency ≥ 80 IU/mL	1112	NP	NP	Invalid test†	NP	NP	1646	1058
Lower limit		560						1116	714
Upper limit		1706						2330	1470
Histamine-sensitizing activity	≥ 95% survival (%)	100	NP	NP	100	NP	NP	100	100

ROXANA MONTEMILONE
DIRECTORA TÉCNICA
SANOFI PASTEUR S.A.

CHRISTIAN DOMINGUEZ
APODERADO
SANOFI PASTEUR S.A.

RA_0301822





sanofi pasteur
352 - Hexaxim

Tests	Acceptance criteria	T0	1 month	2 months	3 months	4 months	5 months	6 months	9 months
Pertussis immunogenicity anti-FHA	Anti-Filamentous Hemagglutinin (FHA) antibody titer obtained for the vaccine is not significantly ($P = 0.95$) less than that of the reference vaccine	Conforms	NP	NP	Conforms	NP	NP	Invalid test†	Conforms
Pertussis immunogenicity anti-PT	Anti-Pertussis Toxoid (PTxd) and antibody titer obtained for the vaccine is not significantly ($P = 0.95$) less than that of the reference vaccine	Conforms	NP	NP	Conforms	NP	NP	Invalid test†	Conforms
Haemophilus immunogenicity	Not less than 50% of the vaccinated mice are seroconverted. Their titer is not less than 4 times that of the pooled control serum	Conforms	NP	NP	Conforms	NP	NP	Conforms	Conforms
Non-adsorbed PT	For information ($\mu\text{g/mL}$)†	< 2.5	NP	NP	< 2.5	NP	NP	< 2.5	< 2.5
Non-adsorbed FHA	For information ($\mu\text{g/mL}$)†	< 2.5	NP	NP	< 2.5	NP	NP	< 2.5	< 2.5
Percent adsorption – tetanus toxoid	For information (%)	18	NP	NP	16	NP	NP	31	32
Percent adsorption – diphtheria toxoid	For information	49	NP	NP	52	NP	NP	60	60.5
Rat immunogenicity assay for IPV	For information (relative potency)								
Type 1		0.6	NP	NP	NP	NP	NP	1.3	1.0
Type 2		1.2	NP	NP	NP	NP	NP	1.1	3.2
Type 3		3.1	NP	NP	NP	NP	NP	0.4	0.7

ROXANA MONTEMILONE
DIRECTORA TÉCNICA
SANOFI PASTEUR S.A.

CHRISTIAN DOMINGUEZ
APODERADO
SANOFI PASTEUR S.A.





Section 3.2.P.8.3
Stability Data

sanofi pasteur
352 - Hexaxim

Tests	Acceptance criteria	T0	1 month	2 months	3 months	4 months	5 months	6 months	9 months
D-antigen content	Type 1: 40 – 86 DU\$/mL	56.2	NP	NP	52.0	NP	NP	52.1	48.4
	Type 2: 10 – 18 DU/mL	11.6	NP	NP	12.0	NP	NP	10.8	10.6
	Type 3: 34 – 72 DU/mL	49.2	NP	NP	47.5 at 4 months	NP	NP	45.4 at 7 months	46.2
Percent adsorption – hepatitis B (ELISA)	For information (%)	98	95	93	91	92	91	89	91
Hepatitis B in-vitro relative potency (IVRP)	For information (relative potency)	1.27	NP	NP	1.25	NP	NP	1.51	1.34
Hepatitis B immunogenicity	Upper confidence limit (P = 0.95) of the estimated relative potency is not less than 1.0	1.17	NP	NP	1.48	NP	NP	1.26	1.13
	Lower limit	0.644	NP	NP	0.885	NP	NP	0.748	0.61
Upper limit		2.268	NP	NP	2.655	NP	NP	2.235	2.147
Bacterial and fungal sterility test	No microbial growth	Conforms	NP	NP	NP	NP	NP	Conforms	Conforms

*
ROXANA MONTEMILONE
DIRECTORA TÉCNICA
SANOFI PASTEUR S.A.

CHRISTIAN DOMINGUEZ
APODERADO
SANOFI PASTEUR S.A.

* Not Planned as per protocol
No retest because of proximity of next time point
Expected value : $\leq 2.5 \mu\text{g/mL}$
DU: D-antigen Unit







1.2 Study 2: Marcy P'Etoile Filled Product – Initial Formulation – Stability Data on Long-Term Storage Conditions at +5°C ± 3°C

36 months stability data with the initial formulation on 3 batches of MLE FP are presented in Table 4 to Table 6.



sanofi pasteur
352 - Hexaxim

Table 4: Stability Study Results for Marcy l'Etoile Filled Product Batch S4009 at +5°C ± 3°C

Tests	Acceptance criteria	T0*	3 months	6 months	9 months	12 months	18 months	24 months	30 months	36 months
Appearance	Whitish and cloudy suspension	Conforms	Conforms	Conforms	Conforms	Conforms	Conforms	Conforms	Conforms	Conforms
pH measurement	6.5 - 8.0	7.03	7.11	7.47	7.18	7.28	7.36	7.28	7.32	7.23
Free formaldehyde content	≤ 30 µg/mL	Not Performed†	Not Performed†	Not Performed†	11.68	11.64	12.46	6.24	6.67	12.86
Extractable volume	At least the nominal volume	Conforms	NP†	NP	NP	NP	NP	NP	NP	Conforms
Osmolality measurement	250 - 450 mosmol/kg	Not Performed†	Not Performed†	Not Performed†	337	338	337	336	334	339
Non-adsorbed PRP	≥ 16 µg/mL	20.4	22.6	21.3	24.1	21.9	23.1	23.9	26.2	24.7
Depolymerized PRP	For information (%)	8.7	14.9 at 4 months	16.5	21.1	24.6	30.7	39.2 at 27 months	38.7	40.9
Diphtheria potency : Activity	Activity ≥ 30 IU/mL	41	NP	47	NP	55	33	122	49	59
Lower limit	Lower confidence limit (P = 0.95) of the estimated potency ≥ 20 IU/mL	27	NP	32	NP	39	22	77	35	44
Upper limit		58	NP	68	NP	79	48	230	69	81
Tetanus potency : Activity	Lower confidence limit (P = 0.95) of the estimated potency ≥ 40 IU/mL	555	NP	443	NP	595	669	327	Not Performed†	629
Lower limit		407	NP	322	NP	432	499	194	Not Performed†	416
Upper limit		781	NP	619 at 7 months	NP	804 at 13 months	891 at 19 months	491	Not Performed†	911
Histamine-sensitizing activity	≥ 95% survival (%)	100	NP	NP	NP	100	NP	100	NP	100

ROXANA MONTEMILONE DIRECTORA TÉCNICA SANOFI PASTEUR S.A.
CHRISTIAN DOMINGUEZ APODERADO SANOFI PASTEUR S.A.



